Edition:
United States

Galapagos Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis


Saturday, 20 Oct 2018 06:30pm EDT 

Oct 22 (Reuters) - GALAPAGOS NV ::REPORTED TOGETHER WITH GILEAD SCIENCES ON SUNDAY PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS.FINCH 2 STUDY RESULTS DEMONSTRATE SIGNIFICANT IMPROVEMENT IN RHEUMATOID ARTHRITIS SIGNS, SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE.DATA SUGGEST FILGOTINIB HAS A POTENTIAL ROLE IN ADDRESSING IMPORTANT UNMET NEEDS IN THE TREATMENT OF RHEUMATOID ARTHRITIS.POSITIVE EFFICACY DATA FROM FINCH 2 WERE PREVIOUSLY ANNOUNCED IN SEPTEMBER 2018.ADDITIONAL FINCH 2 DATA TO BE PRESENTED INCLUDE POSITIVE RESULTS ACROSS SEVERAL PATIENT-REPORTED HEALTH-RELATED QUALITY OF LIFE MEASURES.FILGOTINIB DEMONSTRATED A SAFETY PROFILE CONSISTENT WITH EARLIER CLINICAL TRIALS.